Skip to main content
. 2022 Apr 26;12:6800. doi: 10.1038/s41598-022-10961-y

Table 2.

Univariable and multivariable logistic regression analysis of baseline biomarkers associated with significant visual acuity improvement at 12-month.

Variables Univariable P value Multivariable P value
OR (95% CI) OR (95% CI)
Age 3.429 (0.827–14.209) 0.089 1.746 (0.139–21.873 0.666
Axial length (mm) 0.775 (0.424–1.419) 0.409
Spherical equivalent (D) 0.999 (0.728–1.371) 0.994
BCVA baseline 0.989 (0.955–1.023) 0.521
Structural OCT biomarkers
Subfoveal choroidal thickness (μm) 1.053 (1.012–1.096) 0.012* 1.076 (1.010–1.146) 0.023*
Central fovea thickness (μm) 1.006 (0.998–1.014) 0.141
Ellipsoid zone integrity, (%) 4.643 (1.057–20.385) 0.042* 21.078 (1.092–406.842) 0.044*
ELM integrity, (%) 3.361 (0.823–13.722) 0.091 1.953 (0.258–14.777) 0.517
Subretinal fluid, (%) 1.607 (0.233–11.092) 0.630
OCTA biomarkers
Morphology
 Medusa or sea-fan/tangled, (%) 1.773 (0.396–7.932) 0.454
Qualitative biomarkers
Branching vessels, (%) 1.630 (0.411–6.459) 0.487
Anastomotic loops, (%) 0.779 (0.195–3.118) 0.724
Dark halo, (%) 2.062 (0.520–8.175) 0.303
Quantitative biomarkers
CNV size (mm2) 0.974 (0.945–1.004) 0.090 1.013 (0.962–1.065) 0.629
Vessel density (%) 0.979 (0.917–1.044) 0.513
Vessel length density (%) 0.987 (0.888–1.096) 0.804
Vessel diameter 1.054 (0.446–2.493) 0.905
Vessel tortuosity 1.176 (0.001–1.252) 0.973
Fractal dimension 0.915 (0.842–0.994) 0.036* 0.934 (0.833–1.046) 0.236
Lacunarity 0.953 (0.864–1.051) 0.334
No. of anti-VEGF treatments 0.849 (0.553–1.351) 0.490

anti-VEGF: anti- anti-vascular endothelial growth factor; BCVA: best corrected visual acuity; CI: confidence interval; CNV: choroidal neovascularization; ELM: external limiting membrane; D: diopters; No.: numbers; OCT: optical coherence tomography; OCTA: OCT angiography; OR: odds ratio.

*Statistically significant (P < 0.05).